TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26159017

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with physical training and relearning
Number of subjects: 364

Group type: COMPARATOR
Intervention: Physical training and relearning (Control)
Number of subjects: 364
Study: 24953206

Group type: EXPERIMENTAL
Intervention: Triple boceprevir-based antiviral therapy
Number of subjects: 35
Study: 22103798

Group type: EXPERIMENTAL
Intervention: Synchronous coronary artery bypass grafting and carotid endarterectomy
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Isolated coronary artery bypass grafting
Number of subjects: 1160
Study: 19277904

Group type: EXPERIMENTAL
Intervention: IA TPA (22 mg over 2 h)
Number of subjects: 7

Group type: COMPARATOR
Intervention: IV TPA (per NINDS protocol)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: IA TPA
Number of subjects: 7

Group type: COMPARATOR
Intervention: IV TPA
Number of subjects: 7
Study: 17318803

Group type: EXPERIMENTAL
Intervention: Partial nail avulsion with phenol
Number of subjects: 123

Group type: COMPARATOR
Intervention: Partial nail avulsion with matrix excision
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Local application of gentamicin (antibiotic)
Number of subjects: 123
Study: 15545368

Group type: EXPERIMENTAL
Intervention: IgY‐urease yogurt (test group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: IgY‐urease-free yogurt (control group)
Number of subjects: 42
Study: 11443568

Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate (MCC) vaccine after MACP vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meningococcal C conjugate (MCC) vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meningococcal AC polysaccharide (MACP) vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate (MCC) vaccination
Number of subjects: 0
Study: 9860404

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1.4 mg/kg BW, n = 10 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: NaCl 0.9% solution (n = 10 patients)
Number of subjects: 20
Study: 8700604

Group type: EXPERIMENTAL
Intervention: Lullabies
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mother's voice
Number of subjects: 20
Study: 2707048

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g intravenously pre‐operatively)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Clavulanate-potentiated amoxycillin (1200 mg, repeated for 2 more doses if necessary)
Number of subjects: 200
Study: 883332

Group type: EXPERIMENTAL
Intervention: Total mastectomy
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Total mastectomy with postoperative regional radiotherapy
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Total mastectomy without postoperative regional radiotherapy (with axillary dissection if clinically positive nodes developed)
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Segmental mastectomy plus axillary dissection
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Segmental mastectomy plus axillary dissection plus postoperative radiation
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for patients with histologically positive axillary nodes
Number of subjects: 1700
Study: 31948365

Group type: EXPERIMENTAL
Intervention: Stroop task
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Binary classification task
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Markus and Peters arithmetic test
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control
Number of subjects: 210

Group type: COMPARATOR
Intervention: Imagined fatigue
Number of subjects: 210
Study: 31521777

Group type: EXPERIMENTAL
Intervention: Interactive modules on clinical assessment, care planning, and technological dependency
Number of subjects: 94

Group type: COMPARATOR
Intervention: Noncomplex care topics (Control)
Number of subjects: 94
Study: 31625947

Group type: EXPERIMENTAL
Intervention: My Tools 4 Care (MT4C) intervention, accessed for three months.
Number of subjects: 92
Study: 28900452

Group type: EXPERIMENTAL
Intervention: Postpartum home care service
Number of subjects: 276

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 276
Study: 25841289

Group type: EXPERIMENTAL
Intervention: Non-clean technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ideal technique
Number of subjects: 40
Study: 23652330

Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone combined with systemic prednisolone
Number of subjects: 92

Group type: COMPARATOR
Intervention: Systemic prednisolone alone
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Post hoc analysis excluding individuals with profound hearing loss
Number of subjects: 92
Study: 21385249

Group type: EXPERIMENTAL
Intervention: Music therapy (one-hour single music session)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Verbal relaxation (30 minutes of guided relaxation)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 98
Study: 19302392

Group type: EXPERIMENTAL
Intervention: modSLA surface
Number of subjects: 40

Group type: COMPARATOR
Intervention: SLA surface
Number of subjects: 40
Study: 19023677

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 IV over 10 min and gemcitabine 800 mg/m2 IV at 10 mg/m2 per minute on days 1 and 15 of an every-4-weeks schedule with vitamin B12 and folate supplementation
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 63
Study: 15017629

Group type: EXPERIMENTAL
Intervention: Triple therapy with a proton pump inhibitor (PPI), amoxicillin, and clarithromycin; Omeprazole 20 mg or Lansoprazole 30 mg twice daily; Clarithromycin 200 mg 3 times daily; Amoxicillin 500 mg 3 times daily for 1 week
Number of subjects: 336
Study: 11520590

Group type: EXPERIMENTAL
Intervention: Fluoride containing dentifrice (1500 ppm)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fluoride free dentifrice
Number of subjects: 22
Study: 9568665

Group type: EXPERIMENTAL
Intervention: Laparoscopic transabdominal preperitoneal repair
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Open plug and patch repair
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Shouldice's operation
Number of subjects: 240
Study: 9347286

Group type: EXPERIMENTAL
Intervention: High-protein diet (25 E% protein)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Low-protein diet (12 E% protein)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Habitual diet (controls)
Number of subjects: 65
Study: 1774727

Group type: EXPERIMENTAL
Intervention: Patient-controlled infuser system (2.0 mg incremental dose with a 10-minute lock-out interval)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Intramuscular (IM) injections (10-15 mg every three hours)
Number of subjects: 47
Study: 6167759

Group type: EXPERIMENTAL
Intervention: Bleomycin in addition to conventional four drug regimen (vincristine, adriamycin, cyclophosphamide, actinomycin D)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Radiotherapy for local control (4600 rad or 6000 rad)
Number of subjects: 100
Study: 30944103

Group type: EXPERIMENTAL
Intervention: rhNGF eye drops at 20 μg/mL (Group 1: G1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rhNGF eye drops at 4 μg/mL (Group 2: G2)
Number of subjects: 40
Study: 31285214

Group type: EXPERIMENTAL
Intervention: Appointments scheduled with advanced practitioners
Number of subjects: 3742
Study: 26030354

Group type: EXPERIMENTAL
Intervention: Oral vaccination with live attenuated E. ictaluri isolate (1:100 dilution, ∼5 × 10⁶ CFU/g of feed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral vaccination with live attenuated E. ictaluri isolate (1:10 dilution, ∼5 × 10⁷ CFU/g of feed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonvaccinated controls
Number of subjects: 0
Study: 24687088

Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 126
Study: 22562734

Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) training combined with endurance training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Endurance training without WBV
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups (WBV and no-WBV)
Number of subjects: 14
Study: 21314226

Group type: EXPERIMENTAL
Intervention: CAD/DM Smart Form
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CAD/DM Smart Form (on-treatment analysis)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care (on-treatment analysis)
Number of subjects: 10
Study: 18366374

Group type: EXPERIMENTAL
Intervention: Therapeutic play intervention
Number of subjects: 203
Study: 15973964

Group type: EXPERIMENTAL
Intervention: DHEA (25 mg twice daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DHEA (25 mg twice daily) after exercise
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12811776

Group type: EXPERIMENTAL
Intervention: Strength training (14 weeks, 3 times per week, 2 series of 10 repetitions at 80% of 5-repetition maximum)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (age 66.4 ± 1.7 years; n = 7)
Number of subjects: 7
Study: 10488675

Group type: EXPERIMENTAL
Intervention: Chronic stimulation of the motor cortex
Number of subjects: 32
Study: 8961776

Group type: EXPERIMENTAL
Intervention: High-dose gepirone-ER (20-100 mg)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Low-dose gepirone-ER (10-50 mg)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 1383622

Group type: EXPERIMENTAL
Intervention: Ranolazine 240 mg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ranolazine plasma levels above 500 ng/ml
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ranolazine plasma levels below 500 ng/ml
Number of subjects: 104
Study: 2866135

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg once daily
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 30585803

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 100
Study: 29509024

Group type: EXPERIMENTAL
Intervention: Invisalign® cleaning crystals
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Polident®
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Listerine®
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 0.6% sodium hypochlorite
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 2.5% vinegar
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Toothbrushing
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Other four cleaning methods
Number of subjects: 70
Study: 25394855

Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/day) plus aspirin (100 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (100 mg/day)
Number of subjects: 0
Study: 25131413

Group type: EXPERIMENTAL
Intervention: Standardized oral care protocol (twice a day including tooth brushing, tongue brushing, flossing, mouth rinse, and lip care)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual oral care practices
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Standardized oral care protocol
Number of subjects: 51
Study: 22321916

Group type: EXPERIMENTAL
Intervention: Internet-administered cognitive behavioural therapy (ICBT), tailored according to symptom profile.
Number of subjects: 128

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 128
Study: 18593759

Group type: EXPERIMENTAL
Intervention: Methotrexate plus infliximab
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Methotrexate plus placebo
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Methotrexate monotherapy
Number of subjects: 1049
Study: 17324246

Group type: EXPERIMENTAL
Intervention: NS2330 (tesofensine)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: M1 (major metabolite of NS2330)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: NS2330
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Covariate analysis
Number of subjects: 320
Study: 15350881

Group type: EXPERIMENTAL
Intervention: Motorway driving
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional road driving
Number of subjects: 0
Study: 11453961

Group type: EXPERIMENTAL
Intervention: GnRHa + GH
Number of subjects: 30

Group type: COMPARATOR
Intervention: GnRHa alone
Number of subjects: 30
Study: 7687717

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lisinopril (20 mg daily)
Number of subjects: 14
Study: 3771812

Group type: EXPERIMENTAL
Intervention: Erythromycin (333 mg tid)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Triazolam alone
Number of subjects: 16
Study: 29288507

Group type: EXPERIMENTAL
Intervention: Executive function training
Number of subjects: 62

Group type: COMPARATOR
Intervention: Active control group (passive information activities)
Number of subjects: 62
Study: 27497110

Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide-coated bioactive stents (BAS)
Number of subjects: 827

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 827
Study: 25638697

Group type: EXPERIMENTAL
Intervention: Part-task group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole-task group
Number of subjects: 0
Study: 24217262

Group type: EXPERIMENTAL
Intervention: Continuous ventilation (5 ml/kg tidal volume, 5/min frequency, zero end-expiratory pressure)
Number of subjects: 59
Study: 21396775

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Parecoxib + Remifentanil
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ketorolac + Remifentanil
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 16
Study: 18490588

Group type: EXPERIMENTAL
Intervention: Moderate-potency corticosteroid 30 minutes before UV-B exposure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-potency corticosteroid 30 minutes before UV-B exposure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-potency corticosteroid 6 hours after UV-B exposure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moderate-potency corticosteroid 6 hours after UV-B exposure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Moderate-potency corticosteroid 23 hours after UV-B exposure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-potency corticosteroid 23 hours after UV-B exposure
Number of subjects: 20

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 20
Study: 16525677

Group type: EXPERIMENTAL
Intervention: Lymphokine-activated killer (LAK) cell therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (open cholecystectomy)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Esophagectomy without LAK cell therapy
Number of subjects: 15
Study: 14503834

Group type: EXPERIMENTAL
Intervention: Dye extraction method (dissolution in 65% nitric acid)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluid filtration method
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dye penetration method (2% methylene blue)
Number of subjects: 40
Study: 11118174

Group type: EXPERIMENTAL
Intervention: Neuraxial blockade (epidural or spinal anaesthesia)
Number of subjects: 9559
Study: 9107083

Group type: EXPERIMENTAL
Intervention: High doses of recombinant human erythropoietin (rhEpo) 500 U/kg/day for 30 days after transplant
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1347258

Group type: EXPERIMENTAL
Intervention: Cicloprolol (oral, once a day for 2 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 3799768

Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cesarean section
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (vaginal delivery and cesarean section)
Number of subjects: 60
Study: 31392840

Group type: EXPERIMENTAL
Intervention: Insulin tregopil administered 10 to 20 minutes before a meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin tregopil with a 6-hour between-meal interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin tregopil 4-hour group during afternoon meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fiber meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-hour between-meal interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin tregopil
Number of subjects: 0
Study: 30111284

Group type: EXPERIMENTAL
Intervention: Ropivacaine combined with dexmedetomidine
Number of subjects: 114

Group type: COMPARATOR
Intervention: Ropivacaine alone (control group)
Number of subjects: 114
Study: 26636246

Group type: EXPERIMENTAL
Intervention: Baseline effusion-synovitis maximal area
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Follow-up assessment of effusion-synovitis
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Baseline structural measures
Number of subjects: 406
Study: 25903783

Group type: EXPERIMENTAL
Intervention: 7 days of adequate antimicrobial treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: 14 days of adequate antimicrobial treatment
Number of subjects: 0
Study: 23078110

Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF)
Number of subjects: 22
Study: 22142314

Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures (PDS Plus)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Uncoated sutures (PDS II)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Both groups (Triclosan-coated and Uncoated)
Number of subjects: 485
Study: 19819563

Group type: EXPERIMENTAL
Intervention: M&T
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: A-M&T
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: A-M
Number of subjects: 98
Study: 16723783

Group type: EXPERIMENTAL
Intervention: Pilsicainide 50 mg t.i.d. for 2 weeks
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 108
Study: 14982550

Group type: EXPERIMENTAL
Intervention: Computer-generated tailored advice letters
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Standard printed self-help materials (Control)
Number of subjects: 1058
Study: 11738225

Group type: EXPERIMENTAL
Intervention: Home telemonitoring (measuring pulse, BP, weight, video consultations)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Home telemonitoring
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Video consulting
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Telemonitored group
Number of subjects: 24
Study: 9268188

Group type: EXPERIMENTAL
Intervention: Certoparin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 15
Study: 8324212

Group type: EXPERIMENTAL
Intervention: Rifampicin 450 mg + INH 300 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rifampicin 450 mg + INH 300 mg + pyrazinamide 1500 mg
Number of subjects: 16
Study: 3518459

Group type: EXPERIMENTAL
Intervention: Cephradine-tinidazole
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 199

Group type: COMPARATOR
Intervention: Nontreatment (Control)
Number of subjects: 199
Study: 30326632

Group type: EXPERIMENTAL
Intervention: Foxtail millet (50 g/day) for 12 weeks
Number of subjects: 50
Study: 27638495

Group type: EXPERIMENTAL
Intervention: Education, provision of splints, and a home exercise programme
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard care (continuing on the waitlist without hand therapy intervention)
Number of subjects: 128
Study: 24068456

Group type: EXPERIMENTAL
Intervention: Dopamine agonist treatment for 6 months
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dopamine agonist treatment
Number of subjects: 35
Study: 23755954

Group type: COMPARATOR
Intervention: No bed rest (NR)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Bed rest (R)
Number of subjects: 240
Study: 19864294

Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance exercise
Number of subjects: 27

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 27
Study: 18802782

Group type: EXPERIMENTAL
Intervention: ProFiL program (training workshop, communication-network program, consultation service)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90
Study: 15813400

Group type: EXPERIMENTAL
Intervention: Visual feedback distortion in robotic rehabilitation environment
Number of subjects: 3
Study: 12743224

Group type: EXPERIMENTAL
Intervention: ATECO MRV
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (59 patients without IIH)
Number of subjects: 29
Study: 10588299

Group type: EXPERIMENTAL
Intervention: High-dose vitamin and mineral supplements for AMD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose vitamin supplements for cataract
Number of subjects: 0
Study: 8912734

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 400 microg/d for 7 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 7
Study: 1713753

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP) therapy (8 units daily for 3 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Colloid control (similar volume as FFP)
Number of subjects: 72
Study: 6347109

Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate (10 mg) administered intravenously
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo administered intravenously
Number of subjects: 22
Study: 31409388

Group type: EXPERIMENTAL
Intervention: Denosumab in addition to csDMARDs
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional synthetic DMARDs (csDMARDs) alone
Number of subjects: 44
Study: 26838353

Group type: EXPERIMENTAL
Intervention: Immediate therapist self-disclosure
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Non-immediate therapist self-disclosure
Number of subjects: 86

Group type: COMPARATOR
Intervention: No self-disclosure (control)
Number of subjects: 86
Study: 26663632

Group type: EXPERIMENTAL
Intervention: SSRI (paroxetine or citalopram)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Continued CBT
Number of subjects: 58
Study: 25149430

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 0